APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Angiogenesis Therapeutic Agent

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Angiogenesis Therapeutic Agent Industry Growth and Trends Forecast to 2032

Report ID 173963640122 December 2025122 pages

Choose your research edition.

Industry ResearchAngiogenesis Therapeutic Agent Industry Research Report 2026148 pages · $2,950 USDIndustry Growth & TrendsGlobal Angiogenesis Therapeutic Agent Industry Growth and Trends Forecast to 2032122 pages · $3,450 USDMarket StructureGlobal Angiogenesis Therapeutic Agent Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Angiogenesis Therapeutic Agent Market Outlook and Growth Opportunities 2026209 pages · $4,250 USDMarket Analysis & ForecastGlobal Angiogenesis Therapeutic Agent Market Analysis and Forecast 2026-2032202 pages · $4,950 USD

Market perspective

The global Angiogenesis Therapeutic Agent market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Angiogenesis Therapeutic Agent is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Angiogenesis Therapeutic Agent is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Angiogenesis Therapeutic Agent is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Angiogenesis Therapeutic Agent include Sun Pharma, Shanghai Pharmaceuticals, Johnson & Johnson, Novartis AG, Gilead Sciences, Inc., Pfizer, Daiichi Sankyo, Bayer AG and The Geuder Group, MORCHER GmbH, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Angiogenesis Therapeutic Agent market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Angiogenesis Therapeutic Agent market size, estimates, and forecasts are presented in terms of sales volume (k units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Angiogenesis Therapeutic Agent market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Angiogenesis Therapeutic Agent.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Angiogenesis Therapeutic Agent market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Angiogenesis Therapeutic Agent Market by Company

Sun Pharma

Shanghai Pharmaceuticals

Johnson & Johnson

Novartis AG

Gilead Sciences, Inc.

Pfizer

Daiichi Sankyo

Bayer AG

The Geuder Group, MORCHER GmbH

Santen Pharmaceutical Co., Ltd.

Regeneron Pharmaceuticals, Inc.

Otsuka Pharmaceutical Co. Ltd

Novamedika

Medicom Health care

Implandata ophthalmic products GmbH

Genentech, Inc.

Eyetech Inc.

ERC Labs

Becton, Dickinson and Company

Allergan plc

Angiogenesis Therapeutic Agent Segment by Type

Diabetic Retinopathy

Myopic Choroidal Neovascularization

Macular Edema

Macular Degeneration

Angiogenesis Therapeutic Agent Segment by Application

Online Pharmacies

Hospital Pharmacies

Retail Pharmacies

Angiogenesis Therapeutic Agent Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Angiogenesis Therapeutic Agent market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Angiogenesis Therapeutic Agent and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Angiogenesis Therapeutic Agent.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Angiogenesis Therapeutic Agent manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Angiogenesis Therapeutic Agent in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Diabetic Retinopathy Table 2. Major Company of Myopic Choroidal Neovascularization Table 3. Major Company of Macular Edema Table 4. Major Company of Macular Degeneration Table 5. Global Angiogenesis Therapeutic Agent Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 6. Global Angiogenesis Therapeutic Agent Sales by Type (2021-2026) & (k units) Table 7. Global Angiogenesis Therapeutic Agent Sales Market Share in Volume by Type (2021-2026) Table 8. Global Angiogenesis Therapeutic Agent Sales by Type (2021-2026) & (US$ Million) Table 9. Global Angiogenesis Therapeutic Agent Sales Market Share in Value by Type (2021-2026) Table 10. Global Angiogenesis Therapeutic Agent Price by Type (2021-2026) & (US$/unit) Table 11. Global Angiogenesis Therapeutic Agent Sales by Type (2027-2032) & (k units) Table 12. Global Angiogenesis Therapeutic Agent Sales Market Share in Volume by Type (2027-2032) Table 13. Global Angiogenesis Therapeutic Agent Sales by Type (2027-2032) & (US$ Million) Table 14. Global Angiogenesis Therapeutic Agent Sales Market Share in Value by Type (2027-2032) Table 15. Global Angiogenesis Therapeutic Agent Price by Type (2027-2032) & (US$/unit) Table 16. North America Angiogenesis Therapeutic Agent Sales by Type (2021-2026) & (k units) Table 17. North America Angiogenesis Therapeutic Agent Sales by Type (2021-2026) & (US$ Million) Table 18. Europe Angiogenesis Therapeutic Agent Sales by Type (2021-2026) & (k units) Table 19. Europe Angiogenesis Therapeutic Agent Sales by Type (2021-2026) & (US$ Million) Table 20. Asia-Pacific Angiogenesis Therapeutic Agent Sales by Type (2021-2026) & (k units) Table 21. Asia-Pacific Angiogenesis Therapeutic Agent Sales by Type (2021-2026) & (US$ Million) Table 22. Latin America Angiogenesis Therapeutic Agent Sales by Type (2021-2026) & (k units) Table 23. Latin America Angiogenesis Therapeutic Agent Sales by Type (2021-2026) & (US$ Million) Table 24. Middle East and Africa Angiogenesis Therapeutic Agent Sales by Type (2021-2026) & (k units) Table 25. Middle East and Africa Angiogenesis Therapeutic Agent Sales by Type (2021-2026) & (US$ Million) Table 26. Angiogenesis Therapeutic Agent Industry Trends Table 27. Angiogenesis Therapeutic Agent Industry Drivers Table 28. Angiogenesis Therapeutic Agent Industry Opportunities and Challenges Table 29. Angiogenesis Therapeutic Agent Industry Restraints Table 30. Global Angiogenesis Therapeutic Agent Sales Revenue by Company (US$ Million) & (2021-2026) Table 31. Global Angiogenesis Therapeutic Agent Revenue Market Share by Company (2021-2026) Table 32. Global Angiogenesis Therapeutic Agent Sales by Company (2021-2026) & (k units) Table 33. Global Angiogenesis Therapeutic Agent Sales Share by Company (2021-2026) Table 34. Global Angiogenesis Therapeutic Agent Market Price by Company (2021-2026) & (US$/unit) Table 35. Global Angiogenesis Therapeutic Agent Industry Company Ranking, 2024 VS 2025 VS 2026 Table 36. Global Angiogenesis Therapeutic Agent Major Company Production Sites and Headquarters Table 37. Global Angiogenesis Therapeutic Agent Company, Product Type & Application Table 38. Global Angiogenesis Therapeutic Agent Company Establishment Date Table 39. Global Company Market Concentration Ratio (CR5 and HHI) Table 40. Global Angiogenesis Therapeutic Agent by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 41. Global Angiogenesis Therapeutic Agent Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 42. Global Angiogenesis Therapeutic Agent Sales by Region (2021-2026) & (k units) Table 43. Global Angiogenesis Therapeutic Agent Sales Market Share in Volume by Region (2021-2026) Table 44. Global Angiogenesis Therapeutic Agent Sales by Region (2021-2026) & (US$ Million) Table 45. Global Angiogenesis Therapeutic Agent Sales Market Share in Value by Region (2021-2026) Table 46. Global Angiogenesis Therapeutic Agent Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 47. Global Angiogenesis Therapeutic Agent Sales by Region (2027-2032) & (k units) Table 48. Global Angiogenesis Therapeutic Agent Sales Market Share in Volume by Region (2027-2032) Table 49. Global Angiogenesis Therapeutic Agent Sales by Region (2027-2032) & (US$ Million) Table 50. Global Angiogenesis Therapeutic Agent Sales Market Share in Value by Region (2027-2032) Table 51. Global Angiogenesis Therapeutic Agent Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2027-2032) Table 52. Global Angiogenesis Therapeutic Agent Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 53. Global Angiogenesis Therapeutic Agent Sales by Application (2021-2026) & (k units) Table 54. Global Angiogenesis Therapeutic Agent Sales Market Share in Volume by Application (2021-2026) Table 55. Global Angiogenesis Therapeutic Agent Sales by Application (2021-2026) & (US$ Million) Table 56. Global Angiogenesis Therapeutic Agent Sales Market Share in Value by Application (2021-2026) Table 57. Global Angiogenesis Therapeutic Agent Price by Application (2021-2026) & (US$/unit) Table 58. Global Angiogenesis Therapeutic Agent Sales by Application (2027-2032) & (k units) Table 59. Global Angiogenesis Therapeutic Agent Sales Market Share in Volume by Application (2027-2032) Table 60. Global Angiogenesis Therapeutic Agent Sales by Application (2027-2032) & (US$ Million) Table 61. Global Angiogenesis Therapeutic Agent Sales Market Share in Value by Application (2027-2032) Table 62. Global Angiogenesis Therapeutic Agent Price by Application (2027-2032) & (US$/unit) Table 63. North America Angiogenesis Therapeutic Agent Sales by Application (2021-2026) & (k units) Table 64. North America Angiogenesis Therapeutic Agent Sales by Application (2021-2026) & (US$ Million) Table 65. Europe Angiogenesis Therapeutic Agent Sales by Application (2021-2026) & (k units) Table 66. Europe Angiogenesis Therapeutic Agent Sales by Application (2021-2026) & (US$ Million) Table 67. Asia-Pacific Angiogenesis Therapeutic Agent Sales by Application (2021-2026) & (k units) Table 68. Asia-Pacific Angiogenesis Therapeutic Agent Sales by Application (2021-2026) & (US$ Million) Table 69. Latin America Angiogenesis Therapeutic Agent Sales by Application (2021-2026) & (k units) Table 70. Latin America Angiogenesis Therapeutic Agent Sales by Application (2021-2026) & (US$ Million) Table 71. Middle East and Africa Angiogenesis Therapeutic Agent Sales by Application (2021-2026) & (k units) Table 72. Middle East and Africa Angiogenesis Therapeutic Agent Sales by Application (2021-2026) & (US$ Million) Table 73. Sun Pharma Company Information Table 74. Sun Pharma Business Overview Table 75. Sun Pharma Angiogenesis Therapeutic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 76. Sun Pharma Angiogenesis Therapeutic Agent Product Portfolio Table 77. Sun Pharma Recent Development Table 78. Shanghai Pharmaceuticals Company Information Table 79. Shanghai Pharmaceuticals Business Overview Table 80. Shanghai Pharmaceuticals Angiogenesis Therapeutic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 81. Shanghai Pharmaceuticals Angiogenesis Therapeutic Agent Product Portfolio Table 82. Shanghai Pharmaceuticals Recent Development Table 83. Johnson & Johnson Company Information Table 84. Johnson & Johnson Business Overview Table 85. Johnson & Johnson Angiogenesis Therapeutic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 86. Johnson & Johnson Angiogenesis Therapeutic Agent Product Portfolio Table 87. Johnson & Johnson Recent Development Table 88. Novartis AG Company Information Table 89. Novartis AG Business Overview Table 90. Novartis AG Angiogenesis Therapeutic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 91. Novartis AG Angiogenesis Therapeutic Agent Product Portfolio Table 92. Novartis AG Recent Development Table 93. Gilead Sciences, Inc. Company Information Table 94. Gilead Sciences, Inc. Business Overview Table 95. Gilead Sciences, Inc. Angiogenesis Therapeutic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 96. Gilead Sciences, Inc. Angiogenesis Therapeutic Agent Product Portfolio Table 97. Gilead Sciences, Inc. Recent Development Table 98. Pfizer Company Information Table 99. Pfizer Business Overview Table 100. Pfizer Angiogenesis Therapeutic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 101. Pfizer Angiogenesis Therapeutic Agent Product Portfolio Table 102. Pfizer Recent Development Table 103. Daiichi Sankyo Company Information Table 104. Daiichi Sankyo Business Overview Table 105. Daiichi Sankyo Angiogenesis Therapeutic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 106. Daiichi Sankyo Angiogenesis Therapeutic Agent Product Portfolio Table 107. Daiichi Sankyo Recent Development Table 108. Bayer AG Company Information Table 109. Bayer AG Business Overview Table 110. Bayer AG Angiogenesis Therapeutic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 111. Bayer AG Angiogenesis Therapeutic Agent Product Portfolio Table 112. Bayer AG Recent Development Table 113. The Geuder Group, MORCHER GmbH Company Information Table 114. The Geuder Group, MORCHER GmbH Business Overview Table 115. The Geuder Group, MORCHER GmbH Angiogenesis Therapeutic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 116. The Geuder Group, MORCHER GmbH Angiogenesis Therapeutic Agent Product Portfolio Table 117. The Geuder Group, MORCHER GmbH Recent Development Table 118. Santen Pharmaceutical Co., Ltd. Company Information Table 119. Santen Pharmaceutical Co., Ltd. Business Overview Table 120. Santen Pharmaceutical Co., Ltd. Angiogenesis Therapeutic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 121. Santen Pharmaceutical Co., Ltd. Angiogenesis Therapeutic Agent Product Portfolio Table 122. Santen Pharmaceutical Co., Ltd. Recent Development Table 123. Regeneron Pharmaceuticals, Inc. Company Information Table 124. Regeneron Pharmaceuticals, Inc. Business Overview Table 125. Regeneron Pharmaceuticals, Inc. Angiogenesis Therapeutic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 126. Regeneron Pharmaceuticals, Inc. Angiogenesis Therapeutic Agent Product Portfolio Table 127. Regeneron Pharmaceuticals, Inc. Recent Development Table 128. Otsuka Pharmaceutical Co. Ltd Company Information Table 129. Otsuka Pharmaceutical Co. Ltd Business Overview Table 130. Otsuka Pharmaceutical Co. Ltd Angiogenesis Therapeutic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 131. Otsuka Pharmaceutical Co. Ltd Angiogenesis Therapeutic Agent Product Portfolio Table 132. Otsuka Pharmaceutical Co. Ltd Recent Development Table 133. Novamedika Company Information Table 134. Novamedika Business Overview Table 135. Novamedika Angiogenesis Therapeutic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 136. Novamedika Angiogenesis Therapeutic Agent Product Portfolio Table 137. Novamedika Recent Development Table 138. Medicom Health care Company Information Table 139. Medicom Health care Business Overview Table 140. Medicom Health care Angiogenesis Therapeutic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 141. Medicom Health care Angiogenesis Therapeutic Agent Product Portfolio Table 142. Medicom Health care Recent Development Table 143. Implandata ophthalmic products GmbH Company Information Table 144. Implandata ophthalmic products GmbH Business Overview Table 145. Implandata ophthalmic products GmbH Angiogenesis Therapeutic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 146. Implandata ophthalmic products GmbH Angiogenesis Therapeutic Agent Product Portfolio Table 147. Implandata ophthalmic products GmbH Recent Development Table 148. Genentech, Inc. Company Information Table 149. Genentech, Inc. Business Overview Table 150. Genentech, Inc. Angiogenesis Therapeutic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 151. Genentech, Inc. Angiogenesis Therapeutic Agent Product Portfolio Table 152. Genentech, Inc. Recent Development Table 153. Eyetech Inc. Company Information Table 154. Eyetech Inc. Business Overview Table 155. Eyetech Inc. Angiogenesis Therapeutic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 156. Eyetech Inc. Angiogenesis Therapeutic Agent Product Portfolio Table 157. Eyetech Inc. Recent Development Table 158. ERC Labs Company Information Table 159. ERC Labs Business Overview Table 160. ERC Labs Angiogenesis Therapeutic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 161. ERC Labs Angiogenesis Therapeutic Agent Product Portfolio Table 162. ERC Labs Recent Development Table 163. Becton, Dickinson and Company Company Information Table 164. Becton, Dickinson and Company Business Overview Table 165. Becton, Dickinson and Company Angiogenesis Therapeutic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 166. Becton, Dickinson and Company Angiogenesis Therapeutic Agent Product Portfolio Table 167. Becton, Dickinson and Company Recent Development Table 168. Allergan plc Company Information Table 169. Allergan plc Business Overview Table 170. Allergan plc Angiogenesis Therapeutic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 171. Allergan plc Angiogenesis Therapeutic Agent Product Portfolio Table 172. Allergan plc Recent Development Table 173. North America Angiogenesis Therapeutic Agent Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 174. North America Angiogenesis Therapeutic Agent Sales by Country (2021-2026) & (k units) Table 175. North America Angiogenesis Therapeutic Agent Sales Market Share by Country (2021-2026) Table 176. North America Angiogenesis Therapeutic Agent Sales Forecast by Country (2027-2032) & (k units) Table 177. North America Angiogenesis Therapeutic Agent Sales Market Share Forecast by Country (2027-2032) Table 178. North America Angiogenesis Therapeutic Agent Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 179. North America Angiogenesis Therapeutic Agent Market Size by Country (2021-2026) & (US$ Million) Table 180. North America Angiogenesis Therapeutic Agent Market Share by Country (2021-2026) Table 181. North America Angiogenesis Therapeutic Agent Market Size Forecast by Country (2027-2032) & (US$ Million) Table 182. North America Angiogenesis Therapeutic Agent Market Share Forecast by Country (2027-2032) Table 183. Europe Angiogenesis Therapeutic Agent Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 184. Europe Angiogenesis Therapeutic Agent Sales by Country (2021-2026) & (k units) Table 185. Europe Angiogenesis Therapeutic Agent Sales Market Share by Country (2021-2026) Table 186. Europe Angiogenesis Therapeutic Agent Sales Forecast by Country (2027-2032) & (k units) Table 187. Europe Angiogenesis Therapeutic Agent Sales Market Share Forecast by Country (2027-2032) Table 188. Europe Angiogenesis Therapeutic Agent Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 189. Europe Angiogenesis Therapeutic Agent Market Size by Country (2021-2026) & (US$ Million) Table 190. Europe Angiogenesis Therapeutic Agent Market Share by Country (2021-2026) Table 191. Europe Angiogenesis Therapeutic Agent Market Size Forecast by Country (2027-2032) & (US$ Million) Table 192. Europe Angiogenesis Therapeutic Agent Market Share Forecast by Country (2027-2032) Table 193. Asia-Pacific Angiogenesis Therapeutic Agent Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 194. Asia-Pacific Angiogenesis Therapeutic Agent Sales by Country (2021-2026) & (k units) Table 195. Asia-Pacific Angiogenesis Therapeutic Agent Sales Market Share by Country (2021-2026) Table 196. Asia-Pacific Angiogenesis Therapeutic Agent Sales Forecast by Country (2027-2032) & (k units) Table 197. Asia-Pacific Angiogenesis Therapeutic Agent Sales Market Share Forecast by Country (2027-2032) Table 198. Asia-Pacific Angiogenesis Therapeutic Agent Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 199. Asia-Pacific Angiogenesis Therapeutic Agent Market Size by Country (2021-2026) & (US$ Million) Table 200. Asia-Pacific Angiogenesis Therapeutic Agent Market Share by Country (2021-2026) Table 201. Asia-Pacific Angiogenesis Therapeutic Agent Market Size Forecast by Country (2027-2032) & (US$ Million) Table 202. Asia-Pacific Angiogenesis Therapeutic Agent Market Share Forecast by Country (2027-2032) Table 203. Latin America Angiogenesis Therapeutic Agent Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 204. Latin America Angiogenesis Therapeutic Agent Sales by Country (2021-2026) & (k units) Table 205. Latin America Angiogenesis Therapeutic Agent Sales Market Share by Country (2021-2026) Table 206. Latin America Angiogenesis Therapeutic Agent Sales Forecast by Country (2027-2032) & (k units) Table 207. Latin America Angiogenesis Therapeutic Agent Sales Market Share Forecast by Country (2027-2032) Table 208. Latin America Angiogenesis Therapeutic Agent Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 209. Latin America Angiogenesis Therapeutic Agent Market Size by Country (2021-2026) & (US$ Million) Table 210. Latin America Angiogenesis Therapeutic Agent Market Share by Country (2021-2026) Table 211. Latin America Angiogenesis Therapeutic Agent Market Size Forecast by Country (2027-2032) & (US$ Million) Table 212. Latin America Angiogenesis Therapeutic Agent Market Share Forecast by Country (2027-2032) Table 213. Middle East and Africa Angiogenesis Therapeutic Agent Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 214. Middle East and Africa Angiogenesis Therapeutic Agent Sales by Country (2021-2026) & (k units) Table 215. Middle East and Africa Angiogenesis Therapeutic Agent Sales Market Share by Country (2021-2026) Table 216. Middle East and Africa Angiogenesis Therapeutic Agent Sales Forecast by Country (2027-2032) & (k units) Table 217. Middle East and Africa Angiogenesis Therapeutic Agent Sales Market Share Forecast by Country (2027-2032) Table 218. Middle East and Africa Angiogenesis Therapeutic Agent Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 219. Middle East and Africa Angiogenesis Therapeutic Agent Market Size by Country (2021-2026) & (US$ Million) Table 220. Middle East and Africa Angiogenesis Therapeutic Agent Market Share by Country (2021-2026) Table 221. Middle East and Africa Angiogenesis Therapeutic Agent Market Size Forecast by Country (2027-2032) & (US$ Million) Table 222. Middle East and Africa Angiogenesis Therapeutic Agent Market Share Forecast by Country (2027-2032) Table 223. Key Raw Materials Table 224. Raw Materials Key Suppliers Table 225. Angiogenesis Therapeutic Agent Distributors List Table 226. Angiogenesis Therapeutic Agent Customers List Table 227. Research Programs/Design for This Report Table 228. Authors List of This Report Table 229. Secondary Sources Table 230. Primary Sources List of Figures Figure 1. Angiogenesis Therapeutic Agent Image Figure 2. Global Angiogenesis Therapeutic Agent Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Angiogenesis Therapeutic Agent Market Size (2021-2032) & (US$ Million) Figure 4. Global Angiogenesis Therapeutic Agent Sales (2021-2032) & (k units) Figure 5. Diabetic Retinopathy Image Figure 6. Global Diabetic Retinopathy Sales YoY Growth (2021-2032) & (k units) Figure 7. Myopic Choroidal Neovascularization Image Figure 8. Global Myopic Choroidal Neovascularization Sales YoY Growth (2021-2032) & (k units) Figure 9. Macular Edema Image Figure 10. Global Macular Edema Sales YoY Growth (2021-2032) & (k units) Figure 11. Macular Degeneration Image Figure 12. Global Macular Degeneration Sales YoY Growth (2021-2032) & (k units) Figure 13. Global Angiogenesis Therapeutic Agent Market Size Overview by Type (2021-2032) & (US$ Million) Figure 14. Global Angiogenesis Therapeutic Agent Market Share by Type 2025 VS 2032 Figure 15. North America Angiogenesis Therapeutic Agent Sales Market Share in Volume by Type in 2025 Figure 16. North America Angiogenesis Therapeutic Agent Sales Market Share in Value by Type in 2025 Figure 17. Europe Angiogenesis Therapeutic Agent Sales Market Share in Volume by Type in 2025 Figure 18. Europe Angiogenesis Therapeutic Agent Sales Market Share in Value by Type in 2025 Figure 19. Asia-Pacific Angiogenesis Therapeutic Agent Sales Market Share in Volume by Type in 2025 Figure 20. Asia-Pacific Angiogenesis Therapeutic Agent Sales Market Share in Value by Type in 2025 Figure 21. Latin America Angiogenesis Therapeutic Agent Sales Market Share in Volume by Type in 2025 Figure 22. Latin America Angiogenesis Therapeutic Agent Sales Market Share in Value by Type in 2025 Figure 23. Middle East and Africa Angiogenesis Therapeutic Agent Sales Market Share in Volume by Type in 2025 Figure 24. Middle East and Africa Angiogenesis Therapeutic Agent Sales Market Share in Value by Type in 2025 Figure 25. Global Top 5 and 10 Angiogenesis Therapeutic Agent Players Market Share by Revenue in 2025 Figure 26. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Online Pharmacies Image Figure 28. Global Online Pharmacies Sales YoY Growth (2021-2032) & (k units) Figure 29. Hospital Pharmacies Image Figure 30. Global Hospital Pharmacies Sales YoY Growth (2021-2032) & (k units) Figure 31. Retail Pharmacies Image Figure 32. Global Retail Pharmacies Sales YoY Growth (2021-2032) & (k units) Figure 33. Global Angiogenesis Therapeutic Agent Market Size Overview by Application (2021-2032) & (US$ Million) Figure 34. Global Angiogenesis Therapeutic Agent Market Share by Application 2025 VS 2032 Figure 35. North America Angiogenesis Therapeutic Agent Sales Market Share in Volume by Application in 2025 Figure 36. North America Angiogenesis Therapeutic Agent Sales Market Share in Value by Application in 2025 Figure 37. Europe Angiogenesis Therapeutic Agent Sales Market Share in Volume by Application in 2025 Figure 38. Europe Angiogenesis Therapeutic Agent Sales Market Share in Value by Application in 2025 Figure 39. Asia-Pacific Angiogenesis Therapeutic Agent Sales Market Share in Volume by Application in 2025 Figure 40. Asia-Pacific Angiogenesis Therapeutic Agent Sales Market Share in Value by Application in 2025 Figure 41. Latin America Angiogenesis Therapeutic Agent Sales Market Share in Volume by Application in 2025 Figure 42. Latin America Angiogenesis Therapeutic Agent Sales Market Share in Value by Application in 2025 Figure 43. Middle East and Africa Angiogenesis Therapeutic Agent Sales Market Share in Volume by Application in 2025 Figure 44. Middle East and Africa Angiogenesis Therapeutic Agent Sales Market Share in Value by Application in 2025 Figure 45. North America Angiogenesis Therapeutic Agent Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 46. North America Angiogenesis Therapeutic Agent Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. North America Angiogenesis Therapeutic Agent Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. North America Angiogenesis Therapeutic Agent Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Angiogenesis Therapeutic Agent Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 50. Europe Angiogenesis Therapeutic Agent Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe Angiogenesis Therapeutic Agent Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Europe Angiogenesis Therapeutic Agent Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific Angiogenesis Therapeutic Agent Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 54. Asia-Pacific Angiogenesis Therapeutic Agent Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Asia-Pacific Angiogenesis Therapeutic Agent Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Asia-Pacific Angiogenesis Therapeutic Agent Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Angiogenesis Therapeutic Agent Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 58. Latin America Angiogenesis Therapeutic Agent Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America Angiogenesis Therapeutic Agent Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Latin America Angiogenesis Therapeutic Agent Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa Angiogenesis Therapeutic Agent Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 62. Middle East and Africa Angiogenesis Therapeutic Agent Sales Share by Country: 2021 VS 2025 VS 2032 Figure 63. Middle East and Africa Angiogenesis Therapeutic Agent Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Middle East and Africa Angiogenesis Therapeutic Agent Market Share by Country: 2021 VS 2025 VS 2032 Figure 65. Angiogenesis Therapeutic Agent Value Chain Figure 66. Key Raw Materials Price Figure 67. Manufacturing Cost Structure Figure 68. Angiogenesis Therapeutic Agent Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Diabetic Retinopathy
  • Myopic Choroidal Neovascularization
  • Macular Edema
  • Macular Degeneration
Applications
  • Online Pharmacies
  • Hospital Pharmacies
  • Retail Pharmacies
Companies covered
  • Sun Pharma
  • Shanghai Pharmaceuticals
  • Johnson & Johnson
  • Novartis AG
  • Gilead Sciences, Inc.
  • Pfizer
  • Daiichi Sankyo
  • Bayer AG
  • The Geuder Group, MORCHER GmbH
  • Santen Pharmaceutical Co., Ltd.
  • Regeneron Pharmaceuticals, Inc.
  • Otsuka Pharmaceutical Co. Ltd
  • Novamedika
  • Medicom Health care
  • Implandata ophthalmic products GmbH
  • Genentech, Inc.
  • Eyetech Inc.
  • ERC Labs
  • Becton, Dickinson and Company
  • Allergan plc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Angiogenesis Therapeutic Agent Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Angiogenesis Therapeutic Agent Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Angiogenesis Therapeutic Agent Market by Type
  6. 1.3.1 Diabetic Retinopathy
  7. 1.3.2 Myopic Choroidal Neovascularization
  8. 1.3.3 Macular Edema
  9. 1.3.4 Macular Degeneration
  10. 1.4 Global Angiogenesis Therapeutic Agent Market Size by Type
  11. 1.4.1 Global Angiogenesis Therapeutic Agent Market Size Overview by Type (2021-2032)
  12. 1.4.2 Global Angiogenesis Therapeutic Agent Historic Market Size Review by Type (2021-2026)
  13. 1.4.3 Global Angiogenesis Therapeutic Agent Forecasted Market Size by Type (2027-2032)
  14. 1.5 Key Regions Market Size by Type
  15. 1.5.1 North America Angiogenesis Therapeutic Agent Sales Breakdown by Type (2021-2026)
  16. 1.5.2 Europe Angiogenesis Therapeutic Agent Sales Breakdown by Type (2021-2026)
  17. 1.5.3 Asia-Pacific Angiogenesis Therapeutic Agent Sales Breakdown by Type (2021-2026)
  18. 1.5.4 South America Angiogenesis Therapeutic Agent Sales Breakdown by Type (2021-2026)
  19. 1.5.5 Middle East and Africa Angiogenesis Therapeutic Agent Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Angiogenesis Therapeutic Agent Industry Trends
  2. 2.2 Angiogenesis Therapeutic Agent Industry Drivers
  3. 2.3 Angiogenesis Therapeutic Agent Industry Opportunities and Challenges
  4. 2.4 Angiogenesis Therapeutic Agent Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Angiogenesis Therapeutic Agent Revenue (2021-2026)
  2. 3.2 Global Top Players by Angiogenesis Therapeutic Agent Sales (2021-2026)
  3. 3.3 Global Top Players by Angiogenesis Therapeutic Agent Price (2021-2026)
  4. 3.4 Global Angiogenesis Therapeutic Agent Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Angiogenesis Therapeutic Agent Major Company Production Sites & Headquarters
  6. 3.6 Global Angiogenesis Therapeutic Agent Company, Product Type & Application
  7. 3.7 Global Angiogenesis Therapeutic Agent Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Angiogenesis Therapeutic Agent Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Angiogenesis Therapeutic Agent Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Angiogenesis Therapeutic Agent Tier 1, Tier 2, and Tier 3
4 Angiogenesis Therapeutic Agent Regional Status and Outlook
  1. 4.1 Global Angiogenesis Therapeutic Agent Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Angiogenesis Therapeutic Agent Historic Market Size by Region
  3. 4.2.1 Global Angiogenesis Therapeutic Agent Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Angiogenesis Therapeutic Agent Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Angiogenesis Therapeutic Agent Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Angiogenesis Therapeutic Agent Forecasted Market Size by Region
  7. 4.3.1 Global Angiogenesis Therapeutic Agent Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Angiogenesis Therapeutic Agent Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Angiogenesis Therapeutic Agent Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Angiogenesis Therapeutic Agent by Application
  1. 5.1 Angiogenesis Therapeutic Agent Market by Application
  2. 5.1.1 Online Pharmacies
  3. 5.1.2 Hospital Pharmacies
  4. 5.1.3 Retail Pharmacies
  5. 5.2 Global Angiogenesis Therapeutic Agent Market Size by Application
  6. 5.2.1 Global Angiogenesis Therapeutic Agent Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Angiogenesis Therapeutic Agent Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Angiogenesis Therapeutic Agent Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Angiogenesis Therapeutic Agent Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Angiogenesis Therapeutic Agent Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Angiogenesis Therapeutic Agent Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Angiogenesis Therapeutic Agent Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Angiogenesis Therapeutic Agent Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Sun Pharma
  2. 6.1.1 Sun Pharma Company Information
  3. 6.1.2 Sun Pharma Business Overview
  4. 6.1.3 Sun Pharma Angiogenesis Therapeutic Agent Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Sun Pharma Angiogenesis Therapeutic Agent Product Portfolio
  6. 6.1.5 Sun Pharma Recent Developments
  7. 6.2 Shanghai Pharmaceuticals
  8. 6.2.1 Shanghai Pharmaceuticals Company Information
  9. 6.2.2 Shanghai Pharmaceuticals Business Overview
  10. 6.2.3 Shanghai Pharmaceuticals Angiogenesis Therapeutic Agent Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Shanghai Pharmaceuticals Angiogenesis Therapeutic Agent Product Portfolio
  12. 6.2.5 Shanghai Pharmaceuticals Recent Developments
  13. 6.3 Johnson & Johnson
  14. 6.3.1 Johnson & Johnson Company Information
  15. 6.3.2 Johnson & Johnson Business Overview
  16. 6.3.3 Johnson & Johnson Angiogenesis Therapeutic Agent Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Johnson & Johnson Angiogenesis Therapeutic Agent Product Portfolio
  18. 6.3.5 Johnson & Johnson Recent Developments
  19. 6.4 Novartis AG
  20. 6.4.1 Novartis AG Company Information
  21. 6.4.2 Novartis AG Business Overview
  22. 6.4.3 Novartis AG Angiogenesis Therapeutic Agent Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Novartis AG Angiogenesis Therapeutic Agent Product Portfolio
  24. 6.4.5 Novartis AG Recent Developments
  25. 6.5 Gilead Sciences, Inc.
  26. 6.5.1 Gilead Sciences, Inc. Company Information
  27. 6.5.2 Gilead Sciences, Inc. Business Overview
  28. 6.5.3 Gilead Sciences, Inc. Angiogenesis Therapeutic Agent Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Gilead Sciences, Inc. Angiogenesis Therapeutic Agent Product Portfolio
  30. 6.5.5 Gilead Sciences, Inc. Recent Developments
  31. 6.6 Pfizer
  32. 6.6.1 Pfizer Company Information
  33. 6.6.2 Pfizer Business Overview
  34. 6.6.3 Pfizer Angiogenesis Therapeutic Agent Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Pfizer Angiogenesis Therapeutic Agent Product Portfolio
  36. 6.6.5 Pfizer Recent Developments
  37. 6.7 Daiichi Sankyo
  38. 6.7.1 Daiichi Sankyo Company Information
  39. 6.7.2 Daiichi Sankyo Business Overview
  40. 6.7.3 Daiichi Sankyo Angiogenesis Therapeutic Agent Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Daiichi Sankyo Angiogenesis Therapeutic Agent Product Portfolio
  42. 6.7.5 Daiichi Sankyo Recent Developments
  43. 6.8 Bayer AG
  44. 6.8.1 Bayer AG Company Information
  45. 6.8.2 Bayer AG Business Overview
  46. 6.8.3 Bayer AG Angiogenesis Therapeutic Agent Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Bayer AG Angiogenesis Therapeutic Agent Product Portfolio
  48. 6.8.5 Bayer AG Recent Developments
  49. 6.9 The Geuder Group, MORCHER GmbH
  50. 6.9.1 The Geuder Group, MORCHER GmbH Company Information
  51. 6.9.2 The Geuder Group, MORCHER GmbH Business Overview
  52. 6.9.3 The Geuder Group, MORCHER GmbH Angiogenesis Therapeutic Agent Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 The Geuder Group, MORCHER GmbH Angiogenesis Therapeutic Agent Product Portfolio
  54. 6.9.5 The Geuder Group, MORCHER GmbH Recent Developments
  55. 6.10 Santen Pharmaceutical Co., Ltd.
  56. 6.10.1 Santen Pharmaceutical Co., Ltd. Company Information
  57. 6.10.2 Santen Pharmaceutical Co., Ltd. Business Overview
  58. 6.10.3 Santen Pharmaceutical Co., Ltd. Angiogenesis Therapeutic Agent Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Santen Pharmaceutical Co., Ltd. Angiogenesis Therapeutic Agent Product Portfolio
  60. 6.10.5 Santen Pharmaceutical Co., Ltd. Recent Developments
  61. 6.11 Regeneron Pharmaceuticals, Inc.
  62. 6.11.1 Regeneron Pharmaceuticals, Inc. Company Information
  63. 6.11.2 Regeneron Pharmaceuticals, Inc. Business Overview
  64. 6.11.3 Regeneron Pharmaceuticals, Inc. Angiogenesis Therapeutic Agent Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Regeneron Pharmaceuticals, Inc. Angiogenesis Therapeutic Agent Product Portfolio
  66. 6.11.5 Regeneron Pharmaceuticals, Inc. Recent Developments
  67. 6.12 Otsuka Pharmaceutical Co. Ltd
  68. 6.12.1 Otsuka Pharmaceutical Co. Ltd Company Information
  69. 6.12.2 Otsuka Pharmaceutical Co. Ltd Business Overview
  70. 6.12.3 Otsuka Pharmaceutical Co. Ltd Angiogenesis Therapeutic Agent Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Otsuka Pharmaceutical Co. Ltd Angiogenesis Therapeutic Agent Product Portfolio
  72. 6.12.5 Otsuka Pharmaceutical Co. Ltd Recent Developments
  73. 6.13 Novamedika
  74. 6.13.1 Novamedika Company Information
  75. 6.13.2 Novamedika Business Overview
  76. 6.13.3 Novamedika Angiogenesis Therapeutic Agent Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 Novamedika Angiogenesis Therapeutic Agent Product Portfolio
  78. 6.13.5 Novamedika Recent Developments
  79. 6.14 Medicom Health care
  80. 6.14.1 Medicom Health care Company Information
  81. 6.14.2 Medicom Health care Business Overview
  82. 6.14.3 Medicom Health care Angiogenesis Therapeutic Agent Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 Medicom Health care Angiogenesis Therapeutic Agent Product Portfolio
  84. 6.14.5 Medicom Health care Recent Developments
  85. 6.15 Implandata ophthalmic products GmbH
  86. 6.15.1 Implandata ophthalmic products GmbH Company Information
  87. 6.15.2 Implandata ophthalmic products GmbH Business Overview
  88. 6.15.3 Implandata ophthalmic products GmbH Angiogenesis Therapeutic Agent Sales, Revenue and Gross Margin (2021-2026)
  89. 6.15.4 Implandata ophthalmic products GmbH Angiogenesis Therapeutic Agent Product Portfolio
  90. 6.15.5 Implandata ophthalmic products GmbH Recent Developments
  91. 6.16 Genentech, Inc.
  92. 6.16.1 Genentech, Inc. Company Information
  93. 6.16.2 Genentech, Inc. Business Overview
  94. 6.16.3 Genentech, Inc. Angiogenesis Therapeutic Agent Sales, Revenue and Gross Margin (2021-2026)
  95. 6.16.4 Genentech, Inc. Angiogenesis Therapeutic Agent Product Portfolio
  96. 6.16.5 Genentech, Inc. Recent Developments
  97. 6.17 Eyetech Inc.
  98. 6.17.1 Eyetech Inc. Company Information
  99. 6.17.2 Eyetech Inc. Business Overview
  100. 6.17.3 Eyetech Inc. Angiogenesis Therapeutic Agent Sales, Revenue and Gross Margin (2021-2026)
  101. 6.17.4 Eyetech Inc. Angiogenesis Therapeutic Agent Product Portfolio
  102. 6.17.5 Eyetech Inc. Recent Developments
  103. 6.18 ERC Labs
  104. 6.18.1 ERC Labs Company Information
  105. 6.18.2 ERC Labs Business Overview
  106. 6.18.3 ERC Labs Angiogenesis Therapeutic Agent Sales, Revenue and Gross Margin (2021-2026)
  107. 6.18.4 ERC Labs Angiogenesis Therapeutic Agent Product Portfolio
  108. 6.18.5 ERC Labs Recent Developments
  109. 6.19 Becton, Dickinson and Company
  110. 6.19.1 Becton, Dickinson and Company Company Information
  111. 6.19.2 Becton, Dickinson and Company Business Overview
  112. 6.19.3 Becton, Dickinson and Company Angiogenesis Therapeutic Agent Sales, Revenue and Gross Margin (2021-2026)
  113. 6.19.4 Becton, Dickinson and Company Angiogenesis Therapeutic Agent Product Portfolio
  114. 6.19.5 Becton, Dickinson and Company Recent Developments
  115. 6.20 Allergan plc
  116. 6.20.1 Allergan plc Company Information
  117. 6.20.2 Allergan plc Business Overview
  118. 6.20.3 Allergan plc Angiogenesis Therapeutic Agent Sales, Revenue and Gross Margin (2021-2026)
  119. 6.20.4 Allergan plc Angiogenesis Therapeutic Agent Product Portfolio
  120. 6.20.5 Allergan plc Recent Developments
7 North America by Country
  1. 7.1 North America Angiogenesis Therapeutic Agent Sales by Country
  2. 7.1.1 North America Angiogenesis Therapeutic Agent Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Angiogenesis Therapeutic Agent Sales by Country (2021-2026)
  4. 7.1.3 North America Angiogenesis Therapeutic Agent Sales Forecast by Country (2027-2032)
  5. 7.2 North America Angiogenesis Therapeutic Agent Market Size by Country
  6. 7.2.1 North America Angiogenesis Therapeutic Agent Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Angiogenesis Therapeutic Agent Market Size by Country (2021-2026)
  8. 7.2.3 North America Angiogenesis Therapeutic Agent Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Angiogenesis Therapeutic Agent Sales by Country
  2. 8.1.1 Europe Angiogenesis Therapeutic Agent Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Angiogenesis Therapeutic Agent Sales by Country (2021-2026)
  4. 8.1.3 Europe Angiogenesis Therapeutic Agent Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Angiogenesis Therapeutic Agent Market Size by Country
  6. 8.2.1 Europe Angiogenesis Therapeutic Agent Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Angiogenesis Therapeutic Agent Market Size by Country (2021-2026)
  8. 8.2.3 Europe Angiogenesis Therapeutic Agent Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Angiogenesis Therapeutic Agent Sales by Country
  2. 9.1.1 Asia-Pacific Angiogenesis Therapeutic Agent Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Angiogenesis Therapeutic Agent Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Angiogenesis Therapeutic Agent Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Angiogenesis Therapeutic Agent Market Size by Country
  6. 9.2.1 Asia-Pacific Angiogenesis Therapeutic Agent Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Angiogenesis Therapeutic Agent Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Angiogenesis Therapeutic Agent Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Angiogenesis Therapeutic Agent Sales by Country
  2. 10.1.1 South America Angiogenesis Therapeutic Agent Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Angiogenesis Therapeutic Agent Sales by Country (2021-2026)
  4. 10.1.3 South America Angiogenesis Therapeutic Agent Sales Forecast by Country (2027-2032)
  5. 10.2 South America Angiogenesis Therapeutic Agent Market Size by Country
  6. 10.2.1 South America Angiogenesis Therapeutic Agent Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Angiogenesis Therapeutic Agent Market Size by Country (2021-2026)
  8. 10.2.3 South America Angiogenesis Therapeutic Agent Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Angiogenesis Therapeutic Agent Sales by Country
  2. 11.1.1 Middle East and Africa Angiogenesis Therapeutic Agent Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Angiogenesis Therapeutic Agent Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Angiogenesis Therapeutic Agent Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Angiogenesis Therapeutic Agent Market Size by Country
  6. 11.2.1 Middle East and Africa Angiogenesis Therapeutic Agent Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Angiogenesis Therapeutic Agent Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Angiogenesis Therapeutic Agent Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Angiogenesis Therapeutic Agent Value Chain Analysis
  2. 12.1.1 Angiogenesis Therapeutic Agent Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Angiogenesis Therapeutic Agent Production Mode & Process
  7. 12.2 Angiogenesis Therapeutic Agent Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Angiogenesis Therapeutic Agent Distributors
  10. 12.2.3 Angiogenesis Therapeutic Agent Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst